2024 • Volume • • Electronic publication date: 28/03/2024

Australian Gonococcal Surveillance Program, 1 January to 31 March 2023

Monica M Lahra, Sebastiaan Van Hal, Tiffany R Hogan

# Introduction

The National Neisseria Network (NNN), Australia, established in 1979, comprises reference laboratories in each state and territory. Since 1981, the NNN has reported data for the Australian Gonococcal Surveillance Programme (AGSP), on antimicrobial susceptibility profiles for Neisseria gonorrhoeae isolated from each jurisdiction for an agreed group of agents. The antibiotics reported represent current or potential agents used for the treatment of gonorrhoea, and include ceftriaxone, azithromycin, ciprofloxacin and penicillin. More recently, gentamicin susceptibilities are included in the AGSP Annual Report.

Ceftriaxone, combined with azithromycin, is the recommended treatment regimen for gonorrhoea in the majority of Australia. However, there are substantial geographic differences in susceptibility patterns across Australia, with certain remote regions of the Northern Territory and Western Australia having low gonococcal antimicrobial resistance rates. In these regions, an oral treatment regimen comprising amoxycillin, probenecid, and azithromycin is recommended for the treatment of gonorrhoea. Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP has a programme-specific quality assurance process.

# Results

Table 1 provides a summary of the proportion of Neisseria gonorrhoeae isolates resistant to azithromycin, ciprofloxacin and penicillin for Quarter 1, 2023.

Table 1: **Gonococcal isolates resistant to azithromycin, ciprofloxacin, and penicillin, Australia, 1**January to **31 March 2023, by state or territory**

| Jurisdiction | Number of isolates tested | Resistancea |
| --- | --- | --- |
| Q1, 2023 | Azithromycin | Ciprofloxacin | Penicillin |
| n | % | n | % | n | % |
| Australian Capital Territory | 58 | 4 | 6.9 | 39 | 67.2 | 24 | 41.4 |
| New South Wales | 831 | 44 | 5.3 | 584 | 70.3 | 281 | 33.8 |
| Queensland | 376 | 8 | 2.1 | 201 | 53.5 | 116 | 30.9 |
| South Australia | 155 | 7 | 4.5 | 57 | 36.8 | 50 | 32.3 |
| Tasmania | 28 | 2 | 7.1 | 11 | 39.3 | 8 | 28.6 |
| Victoria | 700 | 36 | 5.1 | 490 | 70.0 | 286 | 40.9 |
| Northern Territory non-remote | 22 | 0 | 0 | 10 | 45.5 | 3 | 13.6 |
| Northern Territory remote | 41 | 0 | 0 | 2 | 4.9 | 2 | 4.9 |
| Western Australia non-remote | 191 | 7 | 3.7 | 89 | 46.6 | 44 | 23.0 |
| Western Australia remote | 11 | 0 | 0 | 6 | 54.5 | 4 | 36.4 |
| Australia | 2,413 | 108 | 4.5 | 1,489 | 61.7 | 818 | 33.9 |

a Resistance as defined by jurisdictional reporting criteria.

## Ceftriaxone

The AGSP has historically reported the category of ceftriaxone decreased susceptibility (DS) at minimum inhibitory concentration (MIC) values ≥ 0.06 mg/L, and has further differentiated those isolates with a MIC ≥ 0.125 mg/L in line with the 2012 World Health Organization criteria.1 In the first quarter of 2023, the proportion of N. gonorrhoeae isolates with ceftriaxone MICs ≥ 0.06 mg/L has waned to 3.81%, subsequent to a surge of such isolates reported in 2022 (5.56%), which peaked in the third quarter of 2022 (7.75%).2,3 The rapid expansion of these isolates (i.e. those with ceftriaxone MIC values 0.06 and 0.125 mg/L) was largely reported from New South Wales and was attributed to multilocus sequence type (MLST) ST-7827 (all resistant to penicillin and ciprofloxacin and susceptible to azithromycin).3 Ongoing jurisdictional genomic analyses continue to monitor for the emergence and expansion of ST-7827 nationally.

In quarter one of 2023, there were seven N. gonorrhoeae isolates from New South Wales (4) and Victoria (3) with ceftriaxone MIC values ≥ 0.125mg/L.1 Genomic analyses detected the presence of the mosaic penA 60.001 allele in five of these isolates, with 2/5 reporting travel to Asia. Increased notifications of N. gonorrhoeae isolates harbouring the penA 60.001 allele have been reported in the United Kingdom, associated with travel from the Asia-Pacific region and conferring ceftriaxone resistance.4 Concerningly, among the five isolates harbouring the mosaic penA 60.001 allele, there were two further instances of extensive drug resistance: ceftriaxone decreased susceptibility (MIC value, 0.25mg/L); high-level azithromycin resistance (MIC values, ≥ 256mg/L); and ciprofloxacin and penicillin resistance.3 Both extensively resistant N. gonorrhoeae isolates were reported from Victoria and identified as ST-16406 strains. Comparative genomic analyses continue as resistant isolates arise. Globally, extensively drug-resistant and ceftriaxone decreased susceptibility N. gonorrhoeae harbouring the mosaic penA 60.001 allele have been sporadic and isolated occurrences.

## Azithromycin

The proportion of isolates resistant to azithromycin in Australia increased in the first quarter of 2023 to 4.5% from 3.9% in 2022 (Table 2), remaining at relatively stable levels since 2019.

It should be noted that there is variation in antimicrobial susceptibility testing methodology in the jurisdictions and so resistance is defined accordingly. The AGSP trend data for azithromycin resistance since 2010 is shown in Table 2.

Globally, there have been reports of increased azithromycin resistance in N. gonorrhoeae, heightened since dual therapy was introduced.5 Notably, there were six isolates nationally in quarter one of 2023 reporting high-level azithromycin resistance (defined as MIC values ≥ 256 mg/L) from Victoria (2) (also exhibiting extensive drug resistance), non-remote Western Australia (2), Queensland (1) and New South Wales (1). Available information for one isolate has indicated travel to Africa. Azithromycin resistance was reported by all jurisdictions in quarter one of 2023, except for the remote regions of Western Australia and of the Northern Territory.

Dual therapy using ceftriaxone plus azithromycin is the recommended treatment for gonorrhoea as a strategy to temper development of more widespread ceftriaxone resistance. Patients with infections in extragenital sites, where the isolate has decreased susceptibility to ceftriaxone, should have test of cure cultures collected. Continued surveillance to monitor N. gonorrhoeae with elevated MIC values, coupled with sentinel site surveillance in high-risk populations, remain essential to inform therapeutic strategies, identify incursion of resistant strains, and detect instances of treatment failure.

**Table 2: Proportion of gonococcal isolates with ceftriaxone MIC values 0.06 and ≥ 0.125 mg/L and resistance to azithromycin, Australia, 2010 to 2022 and 1 January to 31 March 2023**

| Year | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023Q1 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of isolates tested nationally | 4,100 | 4,230 | 4,718 | 4,897 | 4,804 | 5,411 | 6,378 | 7,835 | 9,006 | 9,668 | 7,222 | 6,254 | 8,199 | 2,413 |
| Ceftriaxone MIC 0.06 mg/L | 4.80% | 3.20% | 4.10% | 8.20% | 4.80% | 1.70% | 1.65% | 1.02% | 1.67% | 1.19% | 0.87% | 0.83% | 5.05% | 3.52% |
| Ceftriaxone MIC ≥ 0.125 mg/L | 0.10% | 0.10% | 0.30% | 0.60% | 0.60% | 0.10% | 0.05% | 0.04% | 0.06% | 0.11% | 0.07% | 0.03% | 0.51% | 0.29% |
| **Total proportion of isolates with ceftriaxone MIC values ≥ 0.06 mg/L** | **4.90%** | **3.30%** | **4.40%** | **8.80%** | **5.40%** | **1.80%** | **1.70%** | **1.06%** | **1.73%** | **1.30%** | **0.94%** | **0.86%** | **5.56%** | **3.81%** |
| Azithromycin resistance | n/a | 1.1% | 1.3% | 2.1% | 2.5% | 2.6% | 5.0% | 9.3% | 6.2% | 4.6% | 3.9% | 4.7% | 3.9% | 4.5% |

# Author details

Monica M Lahra1,2

Sebastiaan van Hal3

Tiffany R Hogan1

1. The World Health Organization Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW 2031, Australia
2. School of Medical Sciences, Faculty of Medicine, the University of New South Wales, Kensington, NSW 2052, Australia
3. Molecular Microbiology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia

Corresponding author

Professor Monica M Lahra

The World Health Organization Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, NSW Health Pathology Microbiology, The Prince of Wales Hospital, Randwick, NSW 2031, Australia

Telephone: +61 2 9382 3678

Facsimile: +61 2 9382 3720

Email: monica.lahra@health.nsw.gov.au

# References

1. World Health Organization (WHO). Global action plan to control the spread and impact of antimicrobial resistance in *Neisseria gonorrhoeae*. Geneva: WHO; 2012. Available from: https://apps.who.int/iris/handle/10665/44863.
2. Lahra MM, Hurley SM, van Hal S, Hogan TR. Australian Gonococcal Surveillance Programme, 1 October to 31 December 2022. *Commun Dis Intell (2018)*. 2023;47. doi:  https://doi.org/10.33321/cdi.2023.47.30.
3. Lahra MM, van Hal SJ, Hogan TR. Australian Gonococcal Surveillance Programme Annual Report, 2022. *Commun Dis Intell* (2018) 2023;47. doi: https://doi.org/10.33321/TBA.
4. Day M, Pitt R, Mody N, Saunders J, Rai R, Nori A et al. Detection of 10 cases of ceftriaxone-resistant *Neisseria gonorrhoeae* in the United Kingdom, December 2021 to June 2022. *Euro Surveill*. 2022;27(46):2200803. https://doi.org/10.2807%2F1560-7917.ES.2022.27.46.2200803.
5. Unemo M. Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving *Neisseria gonorrhoeae* continues to challenge. BMC Infect Dis. 2015;15:364. doi:  https://doi.org/10.1186/s12879-015-1029-2.

Communicable Diseases Intelligence

Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Health Protection Policy & Surveillance Division, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.

© 2024 Commonwealth of Australia as represented by the Department of Health and Aged Care

ISSN: 2209-6051 Online

This journal is indexed by Index Medicus and Medline.

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (CC BY-NC-ND) available from https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**

The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at www.pmc.gov.au/resources/commonwealth-coat-arms-information-and-guidelines);
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**

Opinions expressed in *Communicable Diseases Intelligence* are those of the authors and not necessarily those of the Australian Government Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**

Enquiries regarding any other use of this publication should be addressed to the CDI Editor at: cdi.editor@health.gov.au

**Communicable Diseases Network Australia**

Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia. www.health.gov.au/cdna

**Editor**: Christina Bareja • **Deputy Editor**: Simon Petrie • **Design and Production**: Lisa Thompson/Kasra Yousefi

**Editorial Advisory Board**: David Durrheim, Mark Ferson, Clare Huppatz, John Kaldor, Martyn Kirk, Meru Sheel and Steph Williams

**Contacts**

CDI is produced by:

Health Protection Policy & Surveillance Division, Australian Government Department of Health and Aged Care,
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

Website: www.health.gov.au/cdi

Email: cdi.editor@health.gov.au

**Submit an Article**

You are invited to submit your next communicable disease related article to the *Communicable Diseases Intelligence* (CDI) for consideration. More information regarding CDI can be found at: www.health.gov.au/cdi.

Further enquiries should be directed to: cdi.editor@health.gov.au.